Business context and reporting period
Thermo Fisher Scientific Inc. filed this Form 10-K for the fiscal year ended December 31, 2020. The company serves life sciences, diagnostics, analytical instruments, laboratory products and pharmaceutical services markets through four reportable segments. This is an annual filing; standalone fourth-quarter financial results are not clearly provided in the supplied filing text.
Financial performance and liquidity
Amounts are in U.S. dollars. 2020 compared with 2019:
| Metric | 2020 | 2019 |
|---|---|---|
| Revenue | $32.22 billion | $25.54 billion |
| Operating income | $7.79 billion; 24.2% margin | $4.59 billion; 18.0% margin |
| Net income | $6.38 billion | $3.70 billion |
| Diluted EPS | $15.96 | $9.17 |
| Cash provided by operations | $8.29 billion | $4.97 billion |
| Capital expenditures | $1.47 billion | $926 million |
| Income tax provision / effective rate | $850 million / 11.8% | $374 million / 9.2% |
Revenue increased 26% overall, including 25% growth excluding acquisitions, divestitures and currency effects. COVID-19 testing and treatment-related sales were $6.63 billion. Operating income rose 70%; growth in sales and favorable mix were partly offset by strategic growth spending and segment-specific costs.
Segment revenue and operating margin: Life Sciences Solutions, $12.17 billion and 50.2% (versus 35.7%); Analytical Instruments, $5.12 billion and 15.8% (23.1%); Specialty Diagnostics, $5.34 billion and 25.6% (25.0%); Laboratory Products and Services, $12.25 billion and 10.4% (12.5%). Segment margins are management’s segment measure, before specified corporate and acquisition-related items.
At year-end, cash and cash equivalents were $10.33 billion and working capital was $11.65 billion. Debt at carrying value was $21.74 billion, including $2.63 billion of short-term obligations; substantially all short-term debt was redeemed in January 2021. The company had a $3.00 billion revolving credit facility with no borrowings outstanding (availability reduced by $31 million of letters of credit). Management said cash, expected operating cash flow and available borrowing capacity should fund existing business needs for at least 24 months.
Material changes versus the prior period
- Life Sciences Solutions revenue rose 77%, largely on COVID-19 testing demand; Specialty Diagnostics rose 44% and Laboratory Products and Services rose 16%.
- Analytical Instruments revenue fell 7% amid pandemic-related declines in industrial and academic customer activity, although the segment returned to positive growth in Q4.
- Operating margin increased to 24.2% from 18.0%; the comparison includes a $478 million pre-tax gain from the 2019 sale of Anatomical Pathology, while 2020 included $95 million of restructuring and other costs.
- Operating cash flow increased to $8.29 billion from $4.97 billion. Year-end cash rose from $2.40 billion to $10.33 billion, primarily reflecting stronger operating cash flow and 2020 senior-note issuance.
Outlook, commentary, risks and unusual items
- Management expected COVID-related revenues to continue into 2021, but their duration and scale depend principally on testing demand. The pandemic also reduced activity in some businesses; the timing and extent of recovery remained uncertain.
- For 2021, the company forecast an effective tax rate of 11%–13% and capital expenditures of $2.2–$2.4 billion. It did not provide a clear consolidated revenue or earnings outlook in the supplied text.
- In 2020, Analytical Instruments recorded a $108 million charge for a long-term electron-microscopy component supply commitment after developing an alternative product. Unconditional purchase obligations totaled $1.80 billion, mostly expected to be settled in 2021.
- Other notable items include $81 million of financing costs related to a terminated acquisition and $197 million of debt-extinguishment losses recorded in January 2021. The company also disclosed $71 million of environmental liabilities and product liability, workers’ compensation and personal injury accruals of $202 million, net of specified insurance receivables.
- Principal risks include uncertain pandemic-related demand and supply-chain effects, customer spending and market cyclicality, competition and product development, acquisition integration, regulatory and product-quality exposure, litigation, cybersecurity and data privacy, foreign exchange, taxes, and debt obligations. Goodwill was $26.04 billion; impairment depends on future cash flows and valuation assumptions.
- Subsequent events: the company acquired a European viral-vector manufacturing business for approximately $853 million in January 2021 and agreed to acquire Mesa Biotech for $450 million plus up to $100 million of milestone payments.
Investor verification priorities
- Assess how much 2020 growth and profitability depended on the $6.63 billion of COVID-related sales and the sustainability of testing demand.
- Review the recovery trajectory and margin drivers in Analytical Instruments and Laboratory Products and Services.
- Verify the supply-contract charge, remaining purchase commitments, and any further exposure under the component agreement.
- Reconcile debt maturities, January 2021 redemptions and related charges, planned capital spending, acquisitions and share repurchases against liquidity.
- Examine tax benefits and reserves, including the 11%–13% 2021 tax-rate expectation, $1.09 billion of unrecognized tax benefits and $933 million valuation allowance.
- Review environmental, product-liability and other contingencies, and the assumptions supporting goodwill and intangible-asset valuations.